ApoA-I production, purifi cation, and functional cholesterol effl ux and LCAT assays. WT and the mutant apoA-I[D89A/E91A/E92A] were obtained from the culture media of HTB-13 cells grown in roller bottles following infection with adenoviruses expressing the corresponding proteins. For protein production, the culture medium was collected, concentrated 5-fold, dialyzed against 25 mM ammonium bicarbonate, and lyophilized. The lyophilized apoA-I was combined with ␤ -oleoyl-␥ -palmitoyl-L-␣ -phosphatidylcholine (POPC), cholesterol, and sodium cholate at the ratio 1 mg/9.5 mg/0.47 mg/4.5 mg. The proteoliposomes formed were fractionated by density gradient ultracentrifugation, and the fractions that contained pure apoA-I were collected and delipidated three times using 2:1 v/v chloroform:methanol ( 18 ) .
ABCA1-mediated cholesterol effl ux measurements using HEK293-EBNA cells and LCAT activation assays were performed as described ( 13, 19 ) .
Animal studies, plasma lipids and apoA-I levels, FPLC fractionation, and two-dimensional gel electrophoresis. Male apoA-I
Ϫ / Ϫ (ApoA1 tm1Unc ) C57BL/6J mice ( 20 ) were purchased from Jackson Laboratories (Bar Harbor, ME). The mice were maintained on a 12-h light/ dark cycle and standard rodent chow. All procedures performed on the mice were in accordance with National Institutes of Health and institutional guidelines. ApoA-I Ϫ / Ϫ mice, 6-8 weeks of age,
were injected via the tail vein with 2 × 10 9 plaque forming units (pfu) of recombinant adenovirus per animal. The animals were euthanized four days postinjection following a 4 h fast.
The concentration of total cholesterol, free cholesterol, phospholipids, and triglycerides of plasma drawn four days postinfection was determined using the Total Cholesterol E, Free Cholesterol C, and Phospholipids C reagents (Wako Chemicals USA, Inc., Richmond, VA) and INFINITY triglycerides reagent (ThermoScientifi c, Waltham, MA), respectively, according to the manufacturer's instructions. The concentration of cholesteryl esters was determined by subtracting the concentration of free cholesterol from the concentration of total cholesterol. Plasma apoA-I levels were determined by a turbidometric assay using AutoKit A-I (Wako Chemicals). For fast-protein liquid chromatography (FPLC) analysis of plasma, 17 l plasma obtained from mice infected with adenovirus-expressing WT or mutant apoA-I forms were loaded onto a Sepharose 6 PC column (Amersham Biosciences, Piscataway, NJ) in a SMART micro FPLC system (Amersham Biosciences) and eluted with PBS. A total of 25 fractions of 50 l volume each were collected for further analysis. The concentration of lipids in the FPLC fractions was determined as described above. The plasma HDL subpopulations were separated by two-dimensional electrophoresis. The proteins were then transferred to a nitrocellulose membrane and apoA-I was detected by immunoblotting, using the goat polyclonal anti-human apoA-I antibody AB740 (Chemicon International, Billerica, MA) ( 12 ) .
Fractionation of plasma by density gradient ultracentrifugation and EM analysis of the apoA-I-containing fractions. An aliquot of 300 l of plasma obtained from adenovirus-infected mice was diluted with saline to a total volume of 0.5 ml and fractionated by density gradient ultracentrifugation. Following ultracentrifugation, 0.5 ml fractions were collected and analyzed by SDS-PAGE as previously described ( 12 ) . Fractions 6-7 obtained by the density ultracentrifugation, which fl oat in the HDL region, were analyzed by electron microscopy (EM) using a Philips CM-120 electron microscope.
ApoA-I mRNA quantifi cation. Total hepatic RNA was isolated by the Trizol® method (Invitrogen, Carlsbad, CA) according to stable intermediates ( 9, 10 ) ; inhibition of the activation of LCAT ( 9-11 ); and increase in plasma cholesterol or increase in both plasma cholesterol and triglycerides ( 12, 13 ) . These studies also showed that deletion of the 89-99 region increased the levels and density distribution of plasma cholesterol and phospholipids and generated discoidal HDL particles but did not affect plasma triglyceride levels (12) .
In the present study, we investigated the importance of the conserved positively and negatively charged residues present in the 89-99 domain of apoA-I for cholesterol and triglyceride homeostasis and the biogenesis of HDL. In the lipid-bound form, charged residues within the 89-99 region are juxtaposed with the complementary amino acid of apoA-I dimer or hairpin-shaped monomer ( 14, 15 ) and can form solvent-inaccessible salt bridges ( 16 ) . We have found that changes in the positively charged residues K94 and K96 caused structural changes but did not affect the lipid and lipoprotein levels and the biogenesis of HDL. In contrast, substitutions of the negatively charged residues D89, E91, and E92 by alanines altered the conformation of apoA-I, increased its affi nity for VLDL/IDL, as well as for triglyceride-rich emulsions, affected the maturation of HDL, and caused severe hypertriglyceridemia. These fi ndings combined with previous studies suggest that subtle changes in critical amino acids located in different domains of apoA-I may have severe effects not only on the biogenesis of HDL but also on plasma cholesterol and triglyceride homeostasis.
EXPERIMENTAL PROCEDURES

Materials
Materials not mentioned in the experimental procedures have been obtained from sources described previously ( 3, 13 ) .
Methods
Generation of adenoviruses expressing the wild-type (WT) and the mutant apoA-I forms and human lipoprotein lipase. The apoA-I gene lacking the BglII restriction site, which is present at nucleotide position 181 of the genomic sequence relative to the ATG codon of the gene, was cloned into the pCDNA3.1 vector to generate the pCDNA3.1-apoA-I( ⌬ BglII) plasmid as described ( 10 ) . This plasmid was used as a template to introduce the apoA-I mutations apoA-I[D89A/E91A/E92A] and apoA-I[K94A/K96A] using the QuickChange® XL mutagenesis kit (Stratagene, Santa Clara, CA) and the mutagenic primers shown in supplementary Table I . The recombinant adenoviruses were packaged in 911 cells, amplifi ed in human embryonic kidney 293 (HEK 293) cells, purifi ed, and titrated as described ( 10 ) . The adenovirus expressing human lipoprotein lipase (hLPL) was a gift of Dr. Alex Vezeridis ( 17 ) .
Secretion of WT and mutant apoA-I forms. To assess the secretion of WT and mutant apoA-I forms, SW1783 human astrocytoma (HTB-13) cells grown to 80% confl uence in Leibovitz's L-15 medium containing 2% heat-inactivated horse serum in 6-well plates were infected with adenoviruses expressing WT and mutant apoA-I forms at a multiplicity of infection of 10. At 24 h postinfection, the cells were washed twice with PBS and incubated in serum-free medium for 2 h. Following an additional wash with PBS, fresh serum-free medium was added, and 24 h later, it was collected and analyzed by SDS-PAGE for apoA-I expression. 
RESULTS
Expression and secretion of the WT apoA-I and the two apoA-I mutants
To assess the expression and secretion of the two mutant proteins relative to WT apoA-I, we infected HTB-13 cells with recombinant adenoviruses expressing the WT or the mutant apoA-I genes using a multiplicity of infection of 10. Analysis of the medium 24 h postinfection showed that the WT and the two mutant forms of apoA-I were secreted at comparable levels in the medium (supplementary Fig. IA) .
Plasma lipid measurements
Plasma lipids, apoA-I, and hepatic apoA-I mRNA levels were determined four days postinfection of apoA-I Ϫ / Ϫ mice with adenoviruses expressing the WT apoA-I and the two apoA-I mutants. It was found that at comparable levels of mRNA expression the apoA-I[D89A/E91A/E92A] mutant caused dyslipidemia characterized by severe hypertriglyceridemia, increased plasma cholesterol and phospholipids, and decreased cholesteryl ester (CE) to total cholesterol (TC) ratio. The lipid parameters in mice expressing the apoA-I[K94A/K96A] mutant were comparable to those of mice expressing WT apoA-I with the exception of TC/ apoA-I ratio, which was reduced for this mutant ( Table 1 ) .
FPLC profi les of plasma isolated from apoA-I
؊ / ؊ mice infected with adenoviruses expressing the WT apoA-I and the two apoA-I mutants FPLC analysis of plasma from apoA-I Ϫ / Ϫ mice infected with the recombinant adenovirus expressing either WT apoA-I or the two apoA-I mutants showed that, in mice expressing WT apoA-I, cholesterol was distributed predominantly in the HDL2/HDL3 region. The distribution of cholesterol in the apoA-I[K94A/K96A] mutant was similar to that of WT apoA-I with an additional shoulder in the IDL and LDL regions. In contrast, in mice expressing the apoA-I[D89A/E91A/E92A] mutant, cholesterol was distributed predominantly in the VLDL/IDL/LDL region ( Fig. 1A ). All the triglycerides of the apoA-I[D89A/E91A/ E92A] mutant were found in the VLDL region. The VLDL triglyceride peak of the WT apoA-I and apoA-I[K94A/ K96A] mutant were negligible ( Fig. 1B ) .
Fractionation of plasma of mice expressing the WT apoA-I and the two apoA-I mutants by density gradient ultracentrifugation and EM analysis of the HDL fraction
Fractionation of plasma by density gradient ultracentrifugation and subsequent analysis of the resulting fractions by SDS-PAGE served two purposes: it gave important information of the distribution of apoA-I in different lipoprotein fractions, and it provided the HDL fractions that were used for EM analysis. It was found that the WT apoA-I and apoA-I[K94A/K96A] mutant are predominantly distributed in the HDL2 and HDL3 regions ( Fig. 2A , B ) . In contrast, in the case of the apoA-I[D89A/E91A/E92A] mutant, approximately 40% of apoA-I was distributed in the VLDL/IDL/LDL fractions and the remaining in the HDL3 and, to a lesser extent, the HDL2 fractions ( Fig. 2C ) . the manufacturer's instructions. RNA samples were adjusted to 0.1 g/ l, and cDNA was produced using the high-capacity reverse transcriptase cDNA kit (Applied Biosystems, Foster City, CA). Apo A-I mRNA was quantifi ed using Applied Biosystems Gene Array TaqMan® primers for apoA-I cDNA (Cat# Hs00985000_ g1) and 18s rRNA (Cat# 4319413E) with the TaqMan® Gene expression PCR Master Mix (Cat# 4370048), using the Applied Biosystems 7300 Real-Time PCR System ( 21 ).
Preparation of apoA-I for physicochemical measurements. Several days prior to the physicochemical analyses, the lyophilized proteins were dissolved in 4 M guanidine hydrochloride (GndHCl) and then refolded by subsequent dialysis against 2.5 M and 1.25 M GndHCl solutions in PBS, followed by extensive dialysis against the appropriate buffer [10 mM sodium phosphate and 0.02% NaN3 (pH 7.4) for circular dichroism (CD) experiments, PBS for fl uorescence and dimyristoyl-L-␣ -phosphatidylcholine (DMPC) clearance measurements, or Tris for emulsion-binding experiments].
Secondary structure and thermal unfolding of apoA-I forms. Far-UV CD spectra were recorded at 25°C on an AVIV 62DS or AVIV 215 spectropolarimeter (AVIV Associates, Inc., Lakewood, NJ) equipped with a thermoelectric temperature control at protein concentrations 20-55 g/ml as described previously ( 22, 23 ) . For each protein, spectra were recorded at several protein concentrations, then normalized to the protein concentration and expressed as mean residue ellipticity [ ⌰ ], which was calculated by the equation:
where ⌰ is the measured ellipticity, MRW is the mean residue weight (about 115), l is the cell path length (cm), and c is the protein concentration (g/ml). The ␣ -helix content was estimated from the mean residue ellipticity at 222 nm, [ ⌰ 222 ] ( 24 ). Thermal unfolding of apoA-I in solution was monitored by changes in ellipticity at 222 nm. The thermodynamic parameters of the transitions, melting temperature (T m ) and van't Hoff enthalpy ( ⌬ H v ), were determined from the van't Hoff analysis of the melting curves as described previously ( 22, 23 ) .
ANS fl uorescence measurements and DMPC clearance studies. Fluorescence emission spectra of 8-anilino-1-naphthalene-sulfonate (ANS) were recorded in PBS buffer at ANS concentration of 125 M in the presence of 25 g/ml WT apoA-I, mutant apoA-I forms, or carbonic anhydrase, or in the absence of any protein using a FluoroMax-2 fl uorescence spectrometer (25) . The wavelength of maximum fl uorescence (WMF) and the intensity of fl uorescence emission at WMF were determined from each spectra after subtraction of the buffer baseline as described ( 25 ) . The solubilization of DMPC multilamellar vesicles by apoA-I was monitored by the decrease in absorbance at 325 nm following the administration of apoA-I to a suspension of DMPC in PBS as described previously ( 25 ) .
Binding of WT and mutant apoA-I to triglyceride-rich emulsion particles. Triglyceride-rich emulsions were prepared as described ( 26, 27 ) . The particles, which were analyzed for phospholipid and triglyceride content as well as by EM to determine their morphology and size, were used for apoA-I binding assays within two days. For these assays, 120 µg of WT or mutant apoA-I (freshly dialyzed) were incubated for 1 h at 27°C with increasing amounts of emulsion in 1.8 ml of Tris buffer to give a phosphatidylcholine to protein molar ratio ranging from 180 to 710. The apoA-I bound to the emulsions was recovered by ultracentrifugation and quantitated as described ( 27 ) . Experiments were performed three or four times using emulsions from three different preparations. ( Fig. 2D, E ) and the apoA-I[D89A/ E91A/E92A] mutant generated mostly spherical and a few discoidal particles ( Fig. 2F ) . Control experiments showed that HDL density fractions obtained from green fl uorescent protein (GFP) -expressing apoA-I Ϫ / Ϫ mice, which cannot form HDL, contained very few spherical particles (supplementary Fig. II) .
Two-dimensional gel electrophoresis of plasma of mice expressing the WT apoA-I and the two apoA-I mutants Two-dimensional gel electrophoresis of plasma showed that WT apoA-I and the apoA-I[K94A/K96A] mutant formed normal ␣ subpopulations with a small amount of pre ␤ HDL particles ( Fig. 2G, H ) . In contrast, the apoA-I[D89A/ E91A/E92A] mutant formed predominantly pre ␤ 1 and ␣ 4 HDL particles at a ratio of approximately 2:1 ( Fig. 2I ) . Lipoprotein lipase normalizes the lipid and lipoprotein abnormalities induced by the apoA-I[D89A/E91A/E92A] mutation.
ApoA-I Ϫ / Ϫ mice were coinfected with 2 × 10 9 pfu of adenovirus expressing apoA-I[D89A/E91A/E92A] mutant and 5 × 10 8 pfu of adenovirus expressing the hLPL, and their lipid and lipoprotein profi les were compared with those mice infected with 2 × 10 9 pfu of adenovirus expressing WT apoA-I. This analysis showed that the lipoprotein lipase treatment abolished hypertriglyceridemia but did not correct the CE/TC ratio in mice that received the apoA-I[D89A/E91A/E92A] mutant and hLPL ( Table 1 ) .
The plasma of apoA-I Ϫ / Ϫ mice coinfected with the apoA-I[D89A/E91A/E92A] mutant and hLPL was fractionated by density gradient ultracentrifugation and SDS-PAGE, and then the HDL fraction was analyzed by EM. In mice coinfected with the apoA-I[D89A/E91A/E92A] mutant and hLPL, the HDL was distributed mostly into the HDL3 and, to a lesser extent, to HDL2. ApoA-I was not found in the VLDL/IDL fraction ( Fig. 3A ) . The HDL fraction contained both discoidal and spherical HDL particles ( Fig.  3B ) . The observed decrease in plasma apoA-I levels can be explained by the decreased expression of the apoA-I transgene in the coinfection experiment and possibly by faster catabolism of the smaller size HDL particles. Values are means ± SD (n = 4-6). Effect of mutations on the ␣ -helical content, thermal stability, and conformation of apoA-I Analysis of the normalized far-UV CD spectra of WT apoA-I and the apoA-I[D89A/E91A/E92A] and apoA-I[K94A/K96A] mutants ( Fig. 4A ) showed that, compared with WT apoA-I, the two mutant proteins had an ‫ف‬ 9% reduction and ‫ف‬ 6% increase, respectively, in their ␣ -helical content. This fi nding corresponds to a loss of ‫ف‬ 22 and gain of ‫ف‬ 15 residues, respectively, in the helical conformation of apoA-I ( Table 2 ).
The thermal unfolding of the WT apoA-I, apoA-I[D89A/E91A/E92A], and apoA-I[K94A/K96A] mutants was monitored by the ellipticity at 222 nm ( Fig. 4B ) . The parameters of thermal unfolding determined from the van't Hoff analysis are listed in Table 2 . The apoA-I[D89A/ E91A/E92A] mutation caused a small ( ‫ف‬ 2°C) but statistically signifi cant decrease in the melting temperature T m , indicating a destabilizing effect of the mutation. The T m of apoA-I[K94A/K96A] did not differ from that of WT apoA-I. Large ( ‫ف‬ 13 kcal/mol) decrease in the effective enthalpy ⌬ H v for the apoA-I[D89A/E91A/E92A] mutant compared with WT apoA-I was consistent with the less ( Fig. 4C ) . "I" is ANS fl uorescence intensity in relative units compared with the fl uorescence in buffer alone.
d Signifi cance of differences from the value for WT: P < 0.05. e Signifi cance of differences from the value for WT: P < 0.01. f Signifi cance of differences from the value for WT: P < 0.005. Supplemental Material can be found at: Fig. 5B shows that for each emulsion:protein ratio in the incubation mixtures, the number of protein molecules bound to one particle is signifi cantly higher for the apoA-I[D89A/E91A/E92A] mutant than for WT apoA-I.
DISCUSSION
Rationale for selection of the mutations
The 89-99 region of apoA-I contains several residues that are highly conserved in animal species, particularly mammals ( 16 ) . Amino acid position 89 is occupied in 29 species by D and has a conservative E substitution in 2 species. Positions 91 and 92 are occupied by negatively charged E and, in a few cases, D residues in mammals and birds. The cluster of the positively charged K residues at positions 94 and 96 also shows remarkable sequence preservation in amphibian mammals and birds. Position 94 is occupied in 21 species by K and 9 by R, whereas position 96 is occupied by K in all but 1 of the mammals and birds and diverges in fi sh ( 16 ) . It is also interesting that noncharged residues in the 89 to 99 region are conserved. Positions 90, 93, and 97 are occupied mostly by V or other hydrophobic amino acids (supplementary Table II ). Residues D89, E91, E92, K94, and K96 are located in the ␣ 11/3 helical wheel positions 2, 4, 5, 7, and 9, respectively. Residue D89 may form a strong solvent-inaccessible salt bridge with residue R177 of the antiparallel helix, and residues E92 and K96 may form weaker solvent-inaccessible salt bridges with residues R173 and E169, respectively, of the antiparallel helix. Residues E91 and K94 may interact with the aqueous phase.
Previous studies have shown that deletion of the 89-99 region of apoA-I caused dyslipidemia characterized by increased plasma cholesterol and phospholipids that were distributed in the VLDL/IDL region, decreased plasma PLTP activity, normal plasma triglycerides, and formation of discoidal HDL particles. The deletion caused a modest (20-30%) reduction in the capacity of the mutant protein to promote ABCA1-mediated cholesterol effl ux and to activate LCAT in vitro ( 12 ) . The drastic alteration of the structure of apoA-I due to the 89-99 deletion may have caused realignment of the helices of apoA-I on the spherical HDL particles that may be responsible for the observed phenotype.
For these reasons, we chose to further probe the importance of the 89-99 region of apoA-I by focusing on the impact of the conserved clusters of three negatively charged and two positively charged residues on lipid homeostasis and the biogenesis of HDL in mouse models.
The apoA-I mutations D89A/E91A/E92A alter the functions of apoA-I, profoundly affect plasma triglyceride homeostasis, and prevent maturation of HDL
The present study showed that the expression of the apo-I[D89A/E91A/E92A] mutant in apoA-I Ϫ / Ϫ mice resulted in dyslipidemia characterized by severe hypertriglyceridemia, increased plasma cholesterol, decreased HDL cholesterol, reduced esterifi cation of plasma cholesterol, and the generation of a few discoidal HDL particles and smallwas 43% larger and the blue shift in WMF was ‫ف‬ 3 nm greater than in the presence of WT apoA-I ( Fig. 4C and Table 2 ). This fi nding suggests that, compared with WT apoA-I, the [D89A/E91A/E92A] mutant has additional exposed hydrophobic surfaces. The fl uorescence intensity and WMF of the apoA-I[K94A/K96A] were close to those of WT apoA-I ( Fig. 4C and Table 2 ). The kinetics of solubilization of multilamellar DMPC vesicles by WT and the apoA-I[D89A/E91A/E92A] mutant was monitored at 325 nm by the clearance of the turbidity of DMPC suspension following the addition of apoA-I. It was found that the apoA-I[D89A/E91A/E92A] mutant clears turbidity slightly faster than WT apoA-I and the apoA-I[K94/K96A] clears turbidity at a rate similar to that of WT apoA-I ( Fig. 4D ) .
Binding of apoA-I forms to triglyceride-rich emulsions
The weight ratio triolein:PC in the emulsions was 4.1 ± 0.3 (mean ± SD of three isolated emulsions). The average size of particles in a typical isolated emulsion calculated from the electron microphotographs was 54 ± 21 nm (mean± SD; n = 201). The large standard deviations refl ect a broad size distribution that resembles a size distribution of plasma VLDL. Data of the binding assays ( Fig. 5A ) show that at each emulsion:protein ratio in the incubation mixtures, the portion of the bound protein is higher for the apoA-I[D89A/E91A/E92A] mutant than for WT apoA-I. three apoA-I molecules interact with each other on the HDL surface ( 14 ) . Similar but not identical arrangements were proposed in the "trefoil" model where the right-hand half of two antiparallel apoA-I molecules of the double belt model are displaced 60° out of their planar position and are aligned in antiparallel orientation with a third molecule bent on a 60° angle ( 15 ) . In these models the apoA-I monomers or dimers are juxtaposed in the vicinity of helices 5 and 6 ( 14, 15 ) . In these arrangements of apoA-I molecules on sHDL, particle residues E78 in helix 2, D89 in helix 3, and E111 in helix 4 can form solvent-inaccessible salt bridges with residues R188 in helix 8, R177 in helix 7, and H155 in helix 6, respectively, of the antiparallel strand. It is interesting that in the 11/3 ␣ -helical wheel residues, E78, D89, and E111 are all located in wheel position 2. With the exception of R188, all other fi ve residues involved in salt bridges are conserved in mammals. Consistently with these observations, temperature jump molecular dynamic simulation ( 30, 31 ) indicated that the E89-R177 and E111-H155 are more stable than the E78-R188 salt bridge. Thus it is possible that elimination of the negatively charged residues D89 and E111 and, to a lesser extent, E78, may destabilize the intermolecular interactions of the apoA-I dimer or the hairpin bound to HDL and may predispose to dyslipidemia.
The interference of apoA-I[D89A/E91A/E92A] with lipolysis was tested in vivo by coinfection of mice with adenoviruses expressing apoA-I[D89A/E91A/E92A] and human lipoprotein lipase. This treatment abolished hypertriglyceridemia, restored in part the ␣ 1,2,3,4 HDL subpopulations, and redistributed apoA-I in the HDL2 and HDL3 region; however, it did not alter the CE/TC ratio or the formation of discoidal HDL. The fi ndings suggest that the increased abundance of apoA-I in the VLDL/IDL region may create lipoprotein lipase insuffi ciency that induces hypertriglyceridemia.
The present study also indicated a direct effect of the [D89A/E91A/E92A] mutation in the activation of LCAT in vivo. This is documented by the persistence of the discoidal particles, the low CE/TC ratio, and preponderance of the smaller ␣ 4 and ␣ 3 subpopulations following normalization of the plasma triglyceride levels by the lipoprotein lipase treatment. Previous studies have shown that discoidal and small-size HDL particles and the LCAT associated with them may be catabolized quickly by the kidney and thus lead to LCAT insuffi ciency and reduced plasma HDL levels ( 10, 32, 33 ) . In vitro studies have also indicated that increased catabolism by the kidney and liver may occur following triglyceride hydrolysis of hypertriglyceridemic HDL by hepatic lipase ( 34 ) .
It is conceivable that loosening of the structure of apoA-I around the D89 or E92 area due to the substitution of the original residues by A may provide new surfaces for interaction of HDL with other proteins or lipoprotein particles, such as VLDL, in ways that inhibit triglyceride hydrolysis. Furthermore, the accumulation of discoidal HDL and the formation of pre ␤ and small ␣ 4-HDL particles shown by the in vivo experiments indicates that replacement of D89, E91, and E92 by A has a direct impact on the activation of LCAT.
size HDL particles that form pre ␤ and ␣ 4-HDL subpopulations. The mutation caused only a small 15% decrease in plasma PLTP activity (data not shown). On the other hand, the phenotype generated by adenovirus-mediated gene transfer of apoA-I[K94A/K96A] in apoA-I Ϫ / Ϫ mice was normal. These fi ndings suggested that the negatively charged D89, E91, and E92 residues of apoA-I are crucial for maintenance of plasma cholesterol and triglyceride homeostasis as well as the biogenesis and/or catabolism of HDL.
Changes in the structure and the lipid binding properties of the lipid-free apoA-I induced by the D89A/E91A/E92A and the K94A/K96A mutations Estimation of the ␣ -helical content and the thermodynamic stability by far-UV CD spectroscopy indicated that apoA-I[D89A/E91A/E92A] has 22 fewer residues in the ␣ -helical conformation, slightly reduced thermal stability, and greatly reduced cooperativity of thermal unfolding compared with the WT apoA-I ( Table 2 ). ANS fl uorescence measurements indicated that the apoA-I [D89A/ E91A/E92A] mutant has more hydrophobic surfaces exposed to the solvent compared with WT apoA-I, suggesting a looser tertiary folding of the mutant protein. Similar characteristics have been described for the apoA-I[E110A/ E111A] and apoA-I[ ⌬ (61-78)] mutants ( 28 ) that have been previously associated with dyslipidemia ( 12, 13 ) . The apoA-I[K94A/K96A] mutant had increased helical content and reduced cooperativity of thermal unfolding, whereas the ANS characteristics and the DMPC clearance kinetics were similar to those of WT apoA-I.
Potential mechanism of dyslipidemia induced by the D89A/E91A/E92A mutations
The apoA-I[D89A/E91A/E92A] mutant shares two characteristics with the apoA-I[ ⌬ (61-78)] and apoA-I [E110A/E111A] mutants that were shown previously to cause hypertriglyceridemia ( 12, 13 ) . The fi rst characteristic is that all three mutants caused accumulation of apoA-I in the VLDL/IDL region, and as shown previously, this affected the in vitro lipolysis of the VLDL/IDL fraction by exogenous lipoprotein lipase ( 12, 13 ) . The second characteristic of the three apoA-I mutants is that the negatively charged residues E78, D89, and E111 that occur in the WT sequence have the ability to form solvent-inaccessible salt bridges with positively charged residues present in the antiparallel apoA-I molecule of a discoidal HDL particle ( 29 ) . The affi nity of all three mutants for triglyceride-rich lipoproteins is further supported by binding of these mutants to triglyceride-rich emulsion particles (Ref. 27 and Fig. 5 ) .
Analysis of the 93 Å spherical HDL in solution by smallangle neutron scattering (SANS) showed that apoA-I folds around a central lipid core that has 88.4 Å × 62.8 Å dimensions to form a spheroidal HDL (sHDL) particle. Three possible arrangements of the apoA-I on the sHDL particle were considered: 1 ) An "HdHp" model where two apoA-I molecules are arranged in antiparallel planar orientation and a third molecule assumes a hairpin structure; 2 ) a "3Hp" model where three apoA-I molecules are folded as hairpins; and 3 ) an "integrated trimer (iT)" model where Supplemental Material can be found at:
